Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124595
Filing Date
2024-11-12
Accepted
2024-11-12 07:40:23
Documents
52
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q wve-20240930.htm   iXBRL 10-Q 1675560
2 EX-10.1 wve-ex10_1.htm EX-10.1 33640
3 EX-10.2 wve-ex10_2.htm EX-10.2 42536
4 EX-31.1 wve-ex31_1.htm EX-31.1 15516
5 EX-31.2 wve-ex31_2.htm EX-31.2 15658
6 EX-32 wve-ex32.htm EX-32 10604
7 GRAPHIC img57346989_0.jpg GRAPHIC 77988
8 GRAPHIC img57346989_1.jpg GRAPHIC 99712
  Complete submission text file 0000950170-24-124595.txt   5992485

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT wve-20240930.xsd EX-101.SCH 790677
55 EXTRACTED XBRL INSTANCE DOCUMENT wve-20240930_htm.xml XML 643241
Mailing Address 733 CONCORD AVENUE CAMBRIDGE MA 02138
Business Address 7 STRAITS VIEW #12-00, MARINA ONE EAST TOWER SINGAPORE U0 018936 617-949-2900
Wave Life Sciences Ltd. (Filer) CIK: 0001631574 (see all company filings)

EIN.: 000000000 | State of Incorp.: U0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37627 | Film No.: 241443360
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)